At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 319 enrolled
Drug / intervention
sitagliptin phosphate +1 moredrug
Likely dose
sitagliptin phosphate 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -
In Brief
A Phase 3 clinical trial evaluating sitagliptin phosphate and Comparator: voglibose for Diabetes Mellitus, Non-Insulin-Dependent. Completed, enrolled 319 participants.
Detailed Summary
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Non-Insulin-Dependent
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionAug 2007
TodayJul 2026
First PostedDec 14, 2006
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.6 years ago
Interventions
sitagliptin phosphatedrug
sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
Comparator: voglibosedrug
voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks